The latest price target for AEON Biopharma (AMEX:AEON) was reported by Aegis Capital on October 8, 2025. The analyst firm set a price target for $7.20 expecting AEON to fall to within 12 months (a possible NaN% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for AEON Biopharma (AMEX:AEON) was provided by Aegis Capital, and AEON Biopharma reiterated their buy rating.

There is no last upgrade for AEON Biopharma

There is no last downgrade for AEON Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AEON Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AEON Biopharma was filed on October 8, 2025 so you should expect the next rating to be made available sometime around October 8, 2026.

While ratings are subjective and will change, the latest AEON Biopharma (AEON) rating was a reiterated with a price target of $7.20 to $7.20. The current price AEON Biopharma (AEON) is trading at is $undefined, which is out of the analyst’s predicted range.